01 Jun 2021 - 12:33
A signage of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang/File Photo
Reuters
BEIJING: A Wuhan-based affiliate of China National Pharmaceutical Group (Sinopharm) said the start of operations at a new factory will raise the annual production capacity of its COVID-19 vaccine to at least 1 billion doses.
The Wuhan Institute of Biological Products made the announcement in a statement released late on Monday through social media. It did not specify when it will operate the factory at full capacity.
Still, the announcement marks a step toward state-backed Sinopharm s annual capacity target of 3 billion doses for its COVID-19 vaccines.
Sinopharm s Wuhan affiliate boosts COVID-19 shot annual capacity to 1 billion doses Toggle share menu
Advertisement
Sinopharm s Wuhan affiliate boosts COVID-19 shot annual capacity to 1 billion doses A Wuhan-based affiliate of China National Pharmaceutical Group (Sinopharm) said the start of operations at a new factory will raise the annual production capacity of its COVID-19 vaccine to at least 1 billion doses.
FILE PHOTO: A Sinopharm sign is seen at the 2020 China International Fair for Trade in Services (CIFTIS) in Beijing, China, September 5, 2020. REUTERS/Tingshu Wang
01 Jun 2021 12:00PM Share this content
Bookmark
BEIJING: A Wuhan-based affiliate of China National Pharmaceutical Group (Sinopharm) said the start of operations at a new factory will raise the annual production capacity of its COVID-19 vaccine to at least 1 billion doses.
BEIJING, June 1 ― A Wuhan-based affiliate of China National Pharmaceutical Group (Sinopharm) said the start of operations at a new factory will raise the annual production capacity of its Covid-19 vaccine to at least 1 billion doses. The Wuhan Institute of Biological Products made the.
email.
Last week, UNICEF signed an agreement with Human Vaccine, a subsidiary of the Russian Direct Investment Fund, for supply of up to 220 million doses of the Sputnik V COVID-19 vaccine. Procurement of the doses will be contingent on the vaccine receiving emergency use listing from the World Health Organization (WHO) and an advance purchase agreement with Gavi, the Vaccine Alliance, for the COVAX vaccine-sharing facility. The organizations leading COVAX also made an announcement last week renewing the call for funding and vaccine sharing, urging countries to share at least 1 billion doses in 2021. COVAX has so far delivered more than 70 million doses to 126 countries and economies since February, but it will face a shortfall of 190 million doses by the end of June, according to the statement.
BEIJING (Reuters): A Wuhan-based affiliate of China National Pharmaceutical Group (Sinopharm) said the start of operations at a new factory will raise the annual production capacity of its Covid-19 vaccine to at least 1 billion doses.